Research Article
The “CROMa” Project: A Care Pathway for Clinical Management of Patients with Bisphosphonate Exposure
Table 4
Sample distribution of CROMa patients by BRONJ presence.
| | BRONJ ( %)* | Healthy ( %)* | OR (95% CI) |
| Osteometabolic disease | 11 (2,2%) | 387 (97,8%) | — | Metastatic cancer | 17 (16,4%) |
87 (83,6%) | 0.20 (0.11–0.33) |
| | | | for trend 28.82, |
| Therapy intervals | | | | No therapy | 1 (1%) | 92 (99%) | — | <3 years | 7 (3,9%) | 172 (96,1%) | 0.02 (0.01–0.07) | >3 years | 4 (2,7%) | 146 (97,3%) | 0.03 (0.01–0.07) | IV < 8 infusions | 2 (11,8%) | 15 (88,2%) | 0.13 (0.03–0.58) | IV > 8 infusions | 14 (22,2%) | 49 (77,8%) | 0.29 (0.16–0.52) |
| | | | for trend 41.23, |
| Therapy regimen | | | | Association between methods | 0 (0%) | 17 (100%) | — | IV | 17 (11%) | 138 (89%) | 0.12 (0.07–0.20) | IM | 0 (0%) | 60 (100%) | | OS | 11 (4,1%) | 259 (95,9%) | 0.05 (0.02–0.07) |
| | | | for trend 4.31, |
|
|
The percentage ( %) is not absolute but is relative to the specific field.
|